Analyst Insights: Allscripts, Anheuser-Busch, Zumiez, Graco April 3rd

Allscripts Healthcare Solutions, Inc. (NASDAQ:MDRX): Sterne Agee believes that Allscripts’ valuation discount compared with its peers is excessive. The firm doesn’t expect the company to reduce its guidance and it reiterates a $24 target and Buy rating.

Anheuser-Busch InBev (NYSE:BUD): Shares are Buy rated with a Buy rating and $80 price target.

Zumiez, Inc. (NASDAQ:ZUMZ): Baird raised its price target on Zumiez ahead of its release of March comps. The firm expects comps to be in-line with guidance and notes preliminary data suggests March was an especially strong month. Baird also believes Zumiez should be trading at a premium to its historical multiple based on potential upside to estimates. Shares are Outperform rated.

Graco Inc. (NYSE:GGG): Baird raised its price target on Graco following the closing of its ITW Finishing acquisition. The firm believes the acquisition is a strong long-term strategic fit and is raising its estimates to reflect deal accretion. Shares are Outperform rated.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.